BIOMAT Database Logo BIOMAT Database Logo

Loxiglumide inhibits cholecystokinin stimulated somatostatin secretion and simultaneously enhances gastric acid secretion in humans. 1994

M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Department of Gastroenterology and Hepatology, University Hospital St. Radboud, Nijmegen, The Netherlands.

In vitro studies have demonstrated that cholecystokinin releases somatostatin from the gastric mucosa. To date, there is no information about the in vivo significance of this finding in man. Therefore, we have studied the effect of infusion of cholecystokinin resulting in plasma concentrations within the range found after meal-stimulation, on somatostatin release and on gastric acid secretion. In addition we have studied these functions during infusion of the type A cholecystokinin receptor antagonist loxiglumide. In eight healthy subjects, basal gastric acid secretion was distinctly stimulated by cholecystokinin. The effect of cholecystokinin on gastric acid secretion was markedly enhanced by loxiglumide. Cholecystokinin also significantly stimulated somatostatin output into the gastric lumen, but not into the systemic circulation. Somatostatin output into the gastric lumen during infusion of cholecystokinin was abolished by loxiglumide. The data indicate that on the one hand circulating cholecystokinin, like gastrin, stimulates gastric acid secretion probably by binding to less specific type B receptors on parietal cells that are not blocked by loxiglumide, but on the other hand that cholecystokinin, in contrast to gastrin, also inhibits gastric acid secretion probably by binding to specific type A receptors present on somatostatin producing D-cells in the gastric mucosa, that are blocked by loxiglumide.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D011377 Proglumide A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers. Xylamide,Milid,Xilamide
D011949 Receptors, Cholecystokinin Cell surface proteins that bind cholecystokinin (CCK) with high affinity and trigger intracellular changes influencing the behavior of cells. Cholecystokinin receptors are activated by GASTRIN as well as by CCK-4; CCK-8; and CCK-33. Activation of these receptors evokes secretion of AMYLASE by pancreatic acinar cells, acid and PEPSIN by stomach mucosal cells, and contraction of the PYLORUS and GALLBLADDER. The role of the widespread CCK receptors in the central nervous system is not well understood. CCK Receptors,Caerulein Receptors,Cholecystokinin Octapeptide Receptors,Cholecystokinin Receptors,Pancreozymin Receptors,Receptors, CCK,Receptors, Caerulein,Receptors, Pancreozymin,Receptors, Sincalide,Sincalide Receptors,CCK Receptor,CCK-4 Receptors,CCK-8 Receptors,Cholecystokinin Receptor,Receptors, CCK-4,Receptors, CCK-8,Receptors, Cholecystokinin Octapeptide,CCK 4 Receptors,CCK 8 Receptors,Octapeptide Receptors, Cholecystokinin,Receptor, CCK,Receptor, Cholecystokinin,Receptors, CCK 4,Receptors, CCK 8
D002766 Cholecystokinin A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. Pancreozymin,CCK-33,Cholecystokinin 33,Uropancreozymin
D005260 Female Females
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Cholecystokinin inhibits gastric acid secretion through type "A" cholecystokinin receptors and somatostatin in rats.
September 1992, The American journal of physiology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
August 1991, Gastroenterology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Cholecystokinin in the control of gastric acid secretion in humans.
January 1993, Journal of clinical gastroenterology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Somatostatin inhibition of secretagogue and forskolin-stimulated gastric acid secretion.
April 1988, The American journal of physiology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Gastric acidification inhibits meal-stimulated gastric acid secretion after prostaglandin synthesis inhibition by indomethacin in humans.
July 1987, Gastroenterology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
January 2006, Gastroenterology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
January 1998, Arzneimittel-Forschung,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Hyperglycaemia reduces gastrin-stimulated gastric acid secretion in humans.
October 1998, European journal of clinical investigation,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Cimetidine inhibits caffeine-stimulated gastric acid secretion in man.
June 1976, Gastroenterology,
M L Verhulst, and H A Gielkens, and W P Hopman, and A van Schaik, and A Tangerman, and L C Rovati, and J B Jansen
Neurotensin inhibits meal-stimulated gastric acid secretion in man.
November 1983, Scandinavian journal of gastroenterology,
Copied contents to your clipboard!